Compare Davita Inc (DVA) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Microsoft — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while Microsoft trades at $501.74 (market cap $3.76T). The key difference: Microsoft is far larger — about 320.8× Davita Inc's market cap, and Microsoft pays a 0.72% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | MSFT | |
|---|---|---|
Market Cap | $11.72B | $3.76T |
Sector | Health | Technology |
52-Week High | $240.96 | $542.07 |
52-Week Low | $103.87 | $352.83 |
Enterprise Value | $24.44B | $3.74T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Microsoft (MSFT) trades at $503.81, up 0.76% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 estimate. Revenue growth is steady, reaching $281.72B in 2025, supported by a net income margin of 40.31%. Analyst consensus is overwhelmingly positive, with 80.49% buy ratings and a $553.70 price target. Recent news highlights AI leadership and Azure momentum, though concerns over capital expenditures persist.
Outlook remains favorable with AI-driven growth and cloud expansion, but risks include high valuation (P/E 28.19) and competitive pressures. Investment opportunity lies in sustained earnings momentum and dividend stability, while volatility from tech sector shifts and macroeconomic factors warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
